Viewing Study NCT02506959


Ignite Creation Date: 2025-12-24 @ 2:28 PM
Ignite Modification Date: 2026-02-21 @ 11:19 PM
Study NCT ID: NCT02506959
Status: COMPLETED
Last Update Posted: 2025-03-18
First Post: 2015-07-22
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
Sponsor: M.D. Anderson Cancer Center
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Plasma Cell Leukemia View
None Plasmacytoma View
None Recurrent Plasma Cell Myeloma View
None Refractory Plasma Cell Myeloma View
Keywords: